Physician profile
Donna Walker
NPI 1316942535
$1,345.86
in general payments reported to CMS, 2019-2025
21 companies · $19.64 in 2025
The $19.64 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $776 · 2020: $131 · 2022: $12.50 · 2023: $407 · 2025: $19.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $179.34 | 2023 | Imbruvica, Epkinly |
| Ipsen Biopharmaceuticals, INC | $147.30 | 2019-2023 | Tazverik |
| Amgen INC. | $143.98 | 2019 | |
| Incyte Corporation | $119.86 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $119.51 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $99.22 | 2019 | |
| Tesaro, INC. | $75.05 | 2019 | |
| Novartis Pharmaceuticals Corporation | $59.46 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.62 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $53.82 | 2019 | |
| Celgene Corporation | $52.58 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $45.78 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $36.56 | 2019-2025 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $29.86 | 2019 | |
| Pfizer INC. | $29.61 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $26.96 | 2019 | |
| Genzyme Corporation | $20.74 | 2019 | |
| Puma Biotechnology, INC. | $13.80 | 2019 | |
| Coherus Oncology, INC. | $13.78 | 2020 | |
| Janssen Biotech, INC. | $12.50 | 2022 | |
| Astellas Pharma US INC | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.